TPCN1 inhibitors constitute a well-defined chemical class that demonstrates a remarkable ability to modulate a specific cellular function. Within this class, compounds are meticulously crafted to exert their effects on the TPCN1 protein, a pivotal member of the two-pore channel family localized within cellular membranes. The intricate role of TPCN1 revolves around its capacity to orchestrate the flux of ions, notably calcium and sodium ions, across these membranes. This ion transportation is of paramount importance in upholding the delicate balance of ion concentrations within cells and is crucial for various cellular signaling pathways. The structural configuration of TPCN1 inhibitors is meticulously engineered to enable interactions with distinct binding sites on the TPCN1 protein.
Through this interaction, the inhibitors induce alterations in the three-dimensional conformation of the protein, subsequently modulating its ion channel activity. This process occurs without necessitating the inhibitors to partake in any chemical transformations themselves. Instead, they act as regulatory switches, influencing the flow of ions across the membrane. The specificity exhibited by TPCN1 inhibitors towards this particular protein underscores their significance in advancing the understanding of cellular physiology. By selectively targeting TPCN1, these inhibitors offer a unique tool to unravel the intricacies of ion homeostasis, cellular signaling, and other vital cellular processes influenced by ion flux. Their mechanism of action and their capacity to perturb intracellular ion concentrations position TPCN1 inhibitors as invaluable agents for investigating the underlying mechanisms of cellular responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits tyrosine kinases, particularly the BCR-ABL fusion protein in chronic myeloid leukemia (CML). It also targets c-KIT and PDGFR kinases, leading to reduced cell proliferation and survival. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases including VEGFR, PDGFR, and c-KIT, interfering with angiogenesis and tumor growth pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits BCR-ABL, c-KIT, and other kinases. It's used for CML and Ph+ ALL by blocking aberrant signaling pathways. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
Erlotinib targets the epidermal growth factor receptor (EGFR), impeding downstream signaling in cancer cells, commonly used in non-small cell lung carcinoma. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits both EGFR and HER2/neu receptors, reducing their activation and downstream signaling in breast and other cancers. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
Venetoclax targets BCL-2 proteins, promoting apoptosis and approved for certain leukemias. | ||||||